A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

NCT05751226 | Completed Phase 1

• 2 other identifiers: 1458-00022022-002733-34
• Study Type: interventional
• Target: 88
• Locations: 1 country
• Sites: 1

Brief Summary

This study is open to adults between 18 and 55 years of age who are living with overweight or obesity. People with a body mass index (BMI) from 27 to 40 kg/m2 can join the study. The main purpose of this study is to find out how a medicine called BI 1820237 is tolerated by people with overweight or obesity when taken alone or in combination with a medicine called semaglutide or with a medicine called BI 456906. Participants are divided into different groups. All participants in the study either take different doses of BI 1820237 or placebo. Some of the groups take either semaglutide or BI 456906 in addition. Each participant has an equal chance of being in each group. All participants receive the study medicines as injections under the skin once a week for almost 5 months. Placebo injections look like BI 1820237 injections, but do not contain any medicine. Semaglutide is medicine that is already used for overweight or obesity. BI 456906 is another medicine that is being developed for the treatment of overweight and obesity. Participants are in the study for about 7 months. During this time, they visit the study site regularly. For some of the visits, the participants remain at the study site for 1 or 2 nights. At the study visits, the doctors check the health of the participants and note any health problems that could have been caused by BI 1820237, semaglutide, or BI 456906.

Conditions

Healthy; Obesity

Outcome Measures

Primary Outcomes (1)

• Percentage of treatment-emergent adverse events

  assessed as drug-related by the investigator

  Up to 180 days

Secondary Outcomes (2)

• Area under the concentration-time curve of BI 1820237 in plasma over the time interval from 0 to 168 hours after administration of BI 1820237 or placebo (AUC0-168)

  Up to 141 days

• Maximum measured concentration of BI 1820237 in plasma (Cmax)

  Up to 141 days

Study Arms (6)

BI 1820237 treatment group

EXPERIMENTAL

Drug: BI 1820237

Placebo group

PLACEBO COMPARATOR

Drug: Placebo

BI 1820237 + semaglutide treatment group

EXPERIMENTAL

Drug: BI 1820237; Drug: semaglutide

placebo + semaglutide group

ACTIVE COMPARATOR

Drug: semaglutide; Drug: Placebo

BI 1820237 + BI 456906 treatment group

EXPERIMENTAL

Drug: BI 1820237; Drug: BI 456906

placebo + BI 456906 group

ACTIVE COMPARATOR

Drug: Placebo; Drug: BI 456906

Interventions

BI 1820237 DRUG

BI 1820237

BI 1820237 + BI 456906 treatment group; BI 1820237 + semaglutide treatment group; BI 1820237 treatment group

semaglutide DRUG

semaglutide

BI 1820237 + semaglutide treatment group; placebo + semaglutide group

Placebo DRUG

Placebo

Placebo group; placebo + BI 456906 group; placebo + semaglutide group

BI 456906 DRUG

BI 456906

BI 1820237 + BI 456906 treatment group; placebo + BI 456906 group

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female subjects with obesity/overweight (otherwise healthy) according to the assessment of the Investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests
• Age of 18 to 55 years (inclusive)
• Body mass index (BMI) of 27.0 to 40.0 kg/m2 (inclusive). Overweight/obesity should be due to excess adipose tissue, as judged by the Investigator
• Body weight greater than or equal to 75 kg
• Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial

You may not qualify if:

• Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the Investigator
• Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
• Any laboratory value outside the reference range that the Investigator considers to be of clinical relevance
• Any evidence of a concomitant disease assessed as clinically relevant by the Investigator
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
• Cholecystectomy, bariatric surgery or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
• Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders

Sponsors & Collaborators

• Boehringer Ingelheim: lead

Study Sites (1)

CRS Clinical Research Services Mannheim GmbH

Mannheim, 68167, Germany

Location

Related Links

• Related Info

MeSH Terms

Conditions

Obesity

Interventions

semaglutide; BI 456906

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 21, 2023
• First Posted: March 2, 2023
• Study Start: April 11, 2023
• Primary Completion: August 1, 2024
• Study Completion: August 1, 2024
• Last Updated: January 22, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)